trending Market Intelligence /marketintelligence/en/news-insights/trending/ysevpf4jjs7szstqhjoxqa2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

China Biologic Products gets takeover proposal from CITIC Capital unit

Street Talk Episode 68 - As many investors zig away from bank stocks, 2 vets in the space zag toward them

Street Talk Episode 66 - Community banks tap the debt markets while the getting is good

Street Talk Episode 67 - Veteran investor tabs Mick Mulvaney to help with latest financial stock-focused fund

Street Talk Episode 65 - Deferral practices trap US bank portfolios in purgatory

China Biologic Products gets takeover proposal from CITIC Capital unit

China Biologic Products Holdings Inc. received a takeover offer from CCRE Holdings Ltd., a unit of Chinese investment company CITIC Capital Holdings Ltd.

In the preliminary, nonbinding letter, CCRE proposed to acquire all of the outstanding share capital of China Biologic that CCRE does not already own for US$110 per ordinary share in cash — a 30.6% premium to the company's stock volume-weighted average price during the past 30 trading days. The deal values China Biologic at US$3.65 billion.

CCRE intends to finance the acquisition with a combination of debt and equity. The transaction is subject to conditions, including due diligence and execution of definitive agreements.

Between May 21 and June 8, CCRE had purchased 1,680,863 ordinary shares for about US$145.1 million in the open market. The shares represent 5.1% of China Biologic Products.

Upon deal completion, China Biologic would delist its shares from the Nasdaq Global Select Market.

China Biologic Products Holdings is a plasma-based biopharmaceutical company organized under the laws of the Cayman Islands.